BMP-4 Genetic Variants and Protein Expression Are Associated with Platinum-Based Chemotherapy Response and Prognosis in NSCLC

Table 1

Patient characteristics between chemotherapy responder and nonresponders.

Characteristics	Responders	%	Nonresponders	%	𝑃
Age (years)	55.6±6.6		60.7±5.2		0.041
Gender
Male	207	56.9%	328	57.1%	0.494
Female	157	43.1%	246	42.9%
Smoke status
Nonsmokers	84	23.1%	89	15.5%	<0.001
Smoker	280	76.9%	487	84.5%
Histology type
Squamous cell carcinoma	208	57.1%	321	55.9%	0.383
Adenocarcinoma	156	42.9%	253	44.1%
Stage
IIIA	156	42.9%	187	32.6%	0.005
IIIB	119	32.7%	211	36.8%
IV	89	24.5%	176	30.7%
Differentiation
Well	134	36.8%	165	28.7%	0.019
Moderate	129	35.4%	210	36.6%
Poor	101	27.7%	199	34.7%
Chemotherapy regimens
DDP/CBP + TAX/TXT/DOC	156	42.9%	233	40.6%	0.168
DDP/CBP + GEM	121	33.2%	224	39.0%
DDP/CBP + NVB	87	23.9%	117	20.4%

NS: not significance; DDP: cisplatin; CBP: carboplatin; TAX: taxol/paclitaxel; TXT: taxetere; DOC: docetaxel; GEM: gemcitabine; NVB: vinorelbine.